Standards, options and recommendations for hormonal therapy in non-metastatic breast cancer;Réflexions à propos des standards, options et recommandations (SOR) sur l'hormonothérapie dans les cancers du sein non métastatiques

Bulletin du Cancer

Volumn 87, Issue 12, 2000, Pages 948-950

  Vennin, P ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RESEARCH; FEMALE; HEALTH CARE QUALITY; HUMAN; OVARIECTOMY; PRACTICE GUIDELINE; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION TREES; FEMALE; HUMANS; META-ANALYSIS; PRACTICE GUIDELINES; REVIEW LITERATURE; RISK ASSESSMENT;

EID: 0034507497     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Standards, Options et Recommendations (SOR): Hormonothérapie dans les cancers du sein non méastatiques
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
3. Ovarian ablation in early breast cancer: Overview of the randomised trials
4. Tamoxifen for early breast cancer: An overview of the randomised trials
5. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
6. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study
7. A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer